Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical OfficerBrings over thirty years of world-class R&D leadership with particular focus on kidney, liver and oncology and success across the entire spectrum of drug developmentBasel, Switzerland – 03 May 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announced the appointment of Andrea Pellacani, MD, PhD as Chief Medical Officer.In his role as Chief Medical Officer, Dr. Pellacani will play a leading role in guiding the development of breakthrough treatments for fibrotic and rare diseases and associated cancers, using monoclonal…